Clinical-stage pharmaceutical company Altesa BioSciences Inc announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for vapendavir for the treatment of rhinovirus infections in people living with Chronic obstructive pulmonary disease (COPD).
This enables the company to commence clinical trials in the United States for this patient population.
Vapendavir is taken orally in pill form and is a broad-spectrum antiviral medicine that prevents the virus from entering human cells and replicating. According to Altesa, it demonstrates potent activity across 97% of rhinoviruses and other respiratory enteroviruses.
Altesa has exclusive global rights to develop, manufacture and commercialise vapendavir.
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Dupixent receives approval in Japan as first biologic for COPD treatment
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Altesa BioSciences granted US regulatory approval for vapendavir clinical trials
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933